CD274 and cancer: Fourteen patients were on treatment with anti PD-1/PD-L1-based immunotherapy: three of them in the adjuvant setting (cohort B, subgroup B.2) and eleven patients were long lasting responders to immune-based therapies in advanced stage of cancer disease (cohort B, subgroup B.1).